Anixa Biosciences, Inc.
Company Snapshot: Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
- Feb 12 2024 Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
- Jan 29 2024 Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
- Jan 23 2024 Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
- Jan 10 2024 Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024